Interim report
Page 1
Amniotics Interim Report 2nd Quarter 2021 Successful IPO April - June in brief ● ● Events in the quarter The Annual General Meeting , held on April 15 , re - elected Anders Månsson , Christer Fåhraeus , Lars Stigsson and Marcus Larsson as board members , and Christopher Bravery , Fredrik Tiberg . Ingrid Atteryd Heiman and Peter Buhl Jensen were elected as new board members and that Peter Buhl Jensen was elected to serve as chairman of the Board of Directors . The Annual General Meeting resolved to carry out a share split of the company's shares in the ratio 500 : 1 . One existing share of the company will be divided into five hundred shares . After the completion of the split , the number of shares is 12,935,000 . ● Total revenues : SEK 0 ( 0 ) thousand . Operating profit ( EBITDA ) : SEK -17,238 ( -4,859 ) thousand . Result for the period : SEK -17,670 ( 5,260 ) thousand . Earnings per share : SEK -1.11 ( -0.47 ) . Cash and cash equivalents at the end of the reporting period : SEK 8,897 ( 195 ) thousand . The money from the rights issue in June , SEK 60 million , was paid into the company's account in July . Equity / assets ratio as per the end of the reporting period : 88 ( 134 ) % . ● January - June in brief ● The Annual General Meeting resolved to establish an employee stock option program 2021/2026 for employees and senior executives in the company . Amniotics carried out a fully subscribed rights issue that generated SEK 60 million before transaction costs . The Offering consisted of 1,463,415 units . Each unit consisted of two ( 2 ) shares and one ( 1 ) warrant of series TO 1. In total 2,926,830 new shares were issued and the and the number of shares at end of the quarter is 15,861,830 . Total revenues : SEK 0 ( 0 ) thousand . Operating profit ( EBITDA ) : SEK -29,311 ( -10,345 ) thousand . Result for the period : SEK -30,170 ( 11,146 ) thousand . Earnings per share : SEK -1.90 ( -1.00 ) . Cash flow for the period : SEK 8,387 ( -5,517 ) thousand . Events after the end of the reporting period Nasdaq Stockholm approved trading of Amniotics shares and warrants on Nasdaq First North Growth Market and the first day of trading was 6 July 2021 .